 |
 |
|
Home |
Current Issue |
Past Issues |
In the Clinic |
ACP Journal Club |
CME |
Collections |
Audio/Video |
Mobile |
Subscribe |
Tools |
Help |
ACP Online
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
6 March 2001 | Volume 134 Issue 5 | Pages 380-386
Background: Glandular atrophy and intestinal metaplasia are precancerous lesions; whether Helicobacter pylori eradication affects these lesions is controversial.
Objective: To determine whether H. pylori eradication is associated with improvement in glandular atrophy and intestinal metaplasia after at least 1 year.
Design: Single-blind, uncontrolled prospective trial.
Setting: Academic gastroenterology clinic in Japan.
Patients: 163 consecutive patients with dyspepsia and H. pylori infection.
Intervention: One-week course of a proton-pump inhibitor and antibiotic therapy.
Measurements: Endoscopic examination with antral and corporal biopsy was done before treatment and at 1 to 3 and 12 to 15 months after treatment. Gastritis, atrophy, and metaplasia were graded according to the updated Sydney System.
Results: In the 115 patients in whom H. pylori was eradicated, inflammation and mean neutrophil activity had decreased by 1 to 3 months, and both glandular atrophy in the corpus and intestinal metaplasia in the antrum had decreased by 12 to 15 months. Glandular atrophy in the corpus improved in 34 (89%) of 38 patients with atrophy before treatment, and intestinal metaplasia in the antrum improved in 28 (61%) of 46 patients who had metaplasia at baseline. In the 48 patients in whom eradication was unsuccessful, no significant histologic changes were observed.
Conclusion: In the year after successful H. pylori eradication, precancerous lesions improved in most patients.
Author and Article Information
From School of Medicine, Tokyo Medical and Dental University, Tokyo, Japan.
Grant Support: In part by Takeda Chemical Industries, Ltd., Osaka, Japan.
Requests for Single Reprints: Toshifumi Ohkusa, MD, Department of Gastroenterology and Hepatology, School of Medicine, Tokyo Medical and Dental University, 1-5-45 Yushima, Bunkyo-ku, Tokyo 113-8519, Japan; e-mail, ohkusa.gast{at}tmd.ac.jp.
Current Author Addresses: Drs. Ohkusa, Fujiki, Takashimizu, and Watanabe: Department of Gastroenterology and Hepatology, Tokyo Medical and Dental University, 1-5-45 Yushima, Bunkyo-ku, Tokyo 113-8519, Japan.
Drs. Kumagai, Tanizawa, and Eishi: Department of Pathology, Tokyo Medical and Dental University, 1-5-45 Yushima, Bunkyo-ku, Tokyo 113-8519, Japan.
Dr. Yokoyama: Department of Epidemiology, Medical Research Institute, Tokyo Medical and Dental University, 1-5-45 Yushima, Bunkyo-ku, Tokyo 113-8519, Japan.
Author Contributions: Conception and design: T. Ohkusa.
Analysis and interpretation of the data: T. Ohkusa, J. Kumagai, T. Tanizawa, Y. Eishi, T. Yokoyama.
Drafting of the article: T. Ohkusa.
Critical revision of the article for important intellectual content: T. Ohkusa, M. Watanabe.
Final approval of the article: T. Ohkusa, M. Watanabe.
Provision of study materials or patients: T. Ohkusa, K. Fujiki, I. Takashimizu.
Statistical expertise: T. Yokoyama.
Obtaining of funding: T. Ohkusa.
Administrative, technical, or logistic support: K. Fujiki, I. Takashimizu, J. Kumagai, T. Tanizawa, Y. Eishi, T. Yokoyama.
Collection and assembly of data: T. Ohkusa. BRIEF COMMUNICATION
Improvement in Atrophic Gastritis and Intestinal Metaplasia in Patients in Whom Helicobacter pylori Was Eradicated
Related articles in Annals:
This article has been cited by other articles:
|
|
 |
|
  W.-c. You, L. M. Brown, L. Zhang, J.-y. Li, M.-l. Jin, Y.-s. Chang, J.-l. Ma, K.-f. Pan, W.-d. Liu, Y. Hu, et al. Randomized double-blind factorial trial of three treatments to reduce the prevalence of precancerous gastric lesions. J Natl Cancer Inst, July 19, 2006; 98(14): 974 - 983. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R Mera, E T H Fontham, L E Bravo, J C Bravo, M B Piazuelo, M C Camargo, and P Correa Long term follow up of patients treated for Helicobacter pylori infection Gut, November 1, 2005; 54(11): 1536 - 1540. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Farinati, R. Cardin, V. M. Russo, G. Busatto, M. Franco, A. Falda, C. Mescoli, and M. Rugge Differential Effects of Helicobacter pylori Eradication on Oxidative DNA Damage at the Gastroesophageal Junction and at the Gastric Antrum Cancer Epidemiol. Biomarkers Prev., November 1, 2004; 13(11): 1722 - 1728. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W K Leung, S-R Lin, J Y L Ching, K-F To, E K W Ng, F K L Chan, J Y W Lau, and J J Y Sung Factors predicting progression of gastric intestinal metaplasia: results of a randomised trial on Helicobacter pylori eradication Gut, September 1, 2004; 53(9): 1244 - 1249. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E J Kuipers, G F Nelis, E C Klinkenberg-Knol, P Snel, D Goldfain, J J Kolkman, H P M Festen, J Dent, P Zeitoun, N Havu, et al. Cure of Helicobacter pylori infection in patients with reflux oesophagitis treated with long term omeprazole reverses gastritis without exacerbation of reflux disease: results of a randomised controlled trial Gut, January 1, 2004; 53(1): 12 - 20. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Moragoda, R. Jaszewski, P. Kulkarni, and A. P. N. Majumdar Age-associated loss of heterozygosity of tumor suppressor genes in the gastric mucosa of humans Am J Physiol Gastrointest Liver Physiol, June 1, 2002; 282(6): G932 - G936. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. B. Buckingham Helicobacter pylori Eradication Therapy for Nonulcer Dyspepsia Ann Intern Med, April 2, 2002; 136(7): 555 - 555. [Full Text] [PDF]
|
|
|
|
 |
|
 J. G. Fox and T. C. Wang Helicobacter pylori -- Not a Good Bug after All N. Engl. J. Med., September 13, 2001; 345(11): 829 - 832. [Full Text] [PDF]
|
|
Article
